Using Patient Variables in CML to Guide Treatment

News
Video

This video highlights patient variables, including kidney function or history of diabetes, that can help guide treatment in chronic myeloid leukemia.

In this video, Ruediger Hehlmann, MD, of the University of Heidelberg in Germany, discusses patient variables-including kidney function or history of diabetes-that can help guide treatment in chronic myeloid leukemia (CML), and reviews the need for molecular monitoring for disease relapse.

Hehlmann spoke on this topic during an education session at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Related Videos
Findings from a study highlight that 7/8 mismatched unrelated donor posttransplant cyclophosphamide may be a suitable alternative treatment option for those with graft-vs-host disease.
Related Content
The agency recommends that all patients receiving CAR T-cell products should be monitored life-long for secondary malignancy risks.

FDA Mandates New CAR T-Cell Therapy Boxed Warnings in Hematologic Cancers

April 19th 2024
Article

The agency recommends that all patients receiving CAR T-cell products should be monitored life-long for secondary malignancy risks.

Oncology Peer Review On-The-Go: Minority Treatment Disparities and Clinical Trial Enrollment

Oncology Peer Review On-The-Go: Minority Treatment Disparities and Clinical Trial Enrollment

July 6th 2020
Podcast

The first episode of CancerNetwork's podcast Oncology Peer Review On-The-Go explores disparities in cancer care treatment among minorities and the significance of a representative sample in clinical trials.

Phase 2 findings support olutasidenib as a potentially “valuable” treatment option in IDH1-mutated acute myeloid leukemia.

Olutasidenib Yields Enduring Remissions in Previously Treated IDH1+ AML

April 12th 2024
Article

Phase 2 findings support olutasidenib as a potentially “valuable” treatment option in IDH1-mutated acute myeloid leukemia.

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

May 29th 2019
Podcast

Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.

Findings from SELECT-AML-1 support the potential benefit of tamibarotene in those with acute myeloid leukemia harboring RARA gene overexpression.

FDA Grants Fast Track Designation to Tamibarotene in Newly Diagnosed AML

April 10th 2024
Article

Findings from SELECT-AML-1 support the potential benefit of tamibarotene in those with acute myeloid leukemia harboring RARA gene overexpression.

Responses with SLS009 were reported at 60 mg once weekly and 30 mg twice weekly for patients with relapsed/refractory acute myeloid leukemia.

Novel CDK9 Inhibitor Yields Responses in Relapsed/Refractory AML

March 29th 2024
Article

Responses with SLS009 were reported at 60 mg once weekly and 30 mg twice weekly for patients with relapsed/refractory acute myeloid leukemia.